{"database": "lobbying", "table": "lobbying_activities", "rows": [[3389316, "d20a6877-cc48-4b78-b729-ee883fd655f3", "Q2", "FAEGRE DRINKER BIDDLE & REATH LLP", 12631, "TEVA PHARMACEUTICALS USA, INC.", 2025, "second_quarter", "CPT", "Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.", "HOUSE OF REPRESENTATIVES,SENATE", 0, 0, "2025-07-17T15:04:06-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3389316"], "units": {}, "query_ms": 0.599152990616858, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}